News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Viral Genetics Inc. (VRAL) Submits Pre-IND Document for Lyme Disease Drug Candidate to FDA


3/7/2012 7:47:56 AM

SAN MARINO, Calif.--(BUSINESS WIRE)--Viral Genetics (Pinksheets: VRAL) announced today that it has submitted a pre-IND briefing document to the US Food and Drug Administration (FDA) for its Lyme Disease drug candidate, VGV-L, marking important milestones for both the Company and its supporters in the Lyme community.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES